Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2023 Earnings Conference Call November 2, 2023 11:30 AM ET

Company Participants

Wade Walke - Senior Vice President, Investor Relations

Brett Monia - Chief Executive Officer

Onaiza Cadoret - Chief Global Product Strategy & Operations Officer

Richard Geary - Chief Development Officer

Beth Hougen - Chief Financial Officer

Eugene Schneider - Chief Clinical Development Officer

Conference Call Participants

Gary Nachman - Raymond James

Luca Issi - RBC Capital

Yale Jen - Laidlaw & Company

Allison Bratzel - Piper Sandler

Yanan Zhu - Wells Fargo

Kostas Biliouris - BMO Capital Markets

Joseph Stringer - Needle & Company

Myles Minter - William Blair

David Lebowitz - Citi

Operator

Good morning, and welcome to Ionis' Third Quarter 2023 Financial Results Conference Call. As a reminder this call is being recorded.

At this time, I would like to turn the call over Mr. Wade Walke, Senior Vice President of Investor Relations to lead off the call. Please begin, sir.

Wade Walke

Thank you, Chuck. Before we begin I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We have also posted slides on our website that accompany today's call.

With me this morning are Brett Monia, Chief Executive Officer; Onaiza Cadoret, Chief Global Product Strategy and Operations Officer; Richard Geary, Chief Development Officer; and Beth Hougen, Chief Financial Officer; Eric Swayze, Executive Vice President of Research; and Eugene Schneider Chief Clinical Development Officer will also join us for the Q&A portion of the call.

I would like to draw your attention to Slide 3, which contains our forward-looking statement. During this call, we will be making forward-looking language statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.

With that, I'll turn the call over to Brett.

Brett Monia

Thanks, Wade. Good morning, everyone, and thanks for joining us on today's call. Since taking the helm at Ionis nearly four years ago we have executed on a strategy to deliver next level value. And we have done so with a clear vision and laser focus on our strategic objectives to bring our medicines directly to patients build our wholly-owned pipeline and to extend our leadership in oligonucleotide therapeutics.